consenso-venezolano-en-cc3a1ncer-epitelial-de-ovario-2013

Jorge Sánchez Lander y col.
279
UTILIDAD DE LA RADIOTERAPIA EN
CÁNCER AVANZADO DE OVARIO
Se recomienda solamente como segunda línea
de tratamiento en enfermedad residual localizada,
posterior a la administración de la quimioterapia
y que sea considerada irresecable, por ejemplo,
plastrón ganglionar fijo que invade los vasos
ilíacos, la vena cava o la arteria aorta. También
en enfermedad ganglionar inguinal persistente
e irresecable (1-3) .
REFERENCIAS
1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR,
Partridge EE, Look KY, et al. Cyclophosphamide
and cisplatin compared with paclitaxel and cisplatin
in patients with stage III and stage IV ovarian cancer.
N Engl J Med. 1996;334(1):1-6.
2. Di Saia P, Creasman C, Mannel E. En: Disaia P,
editor. Clinical Gynecologic Oncology. 8 a edición.
Filadelfia: Lippincott; 2012.p.285-328.
3. Levine, De Los Santos, Fleming F. Handbook for
principles and practice of Gynecologic Oncology.
Filadelfia: Lippincott; 2010.
4. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-
Pearson D, Burger RA, et al. Phase III Trial of
carboplatin and paclitaxel compared with cisplatin
and paclitaxel in patients with optimally debulked
ovary cancer: A Gynecology Oncology Group Study.
J Clin Oncol. 2003;21(17):3194-31200.
5. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman
R, Atkinson R, et al. Phase III randomized trial of
docetaxel-carboplatin versus paclitaxel-carboplatin
as first-line chemotherapy for ovarian carcinoma. J
Natl Cancer Inst. 2004;96:1682-1691.
6. Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis
E, Ioannidis JP. Survival benefits with diverse
chemotherapy regimens for ovarian cancer: Metaanalysis
of multiple treatments. J Natl Cancer Inst.
2006;98:1655-1663.
7. Du Bois A, Weber B, Rochon J, Meier W, Goupil
A, Olbricht S, et al. Addition of epirubicin as a
third drug to carboplatin-paclitaxel in first-line
treatment of advanced ovarian cancer: A prospectively
randomized gynecologic cancer intergroup trial by
the Arbeitsgemeinschaft Gynaekologische Onkologie
Ovarian Cancer Study Group and the Groupe
d'Investigateurs Nationaux pour l'Etude des Cancers
Ovariens. J Clin Oncol. 2006;24:1127-1135.
8. Bookman MA, Brady MF, McGuire WP, Harper PG,
Alberts DS, Friedlander M, et al. Evaluation of new
platinum-based treatment regimens in advanced-stage
ovarian cancer: A Phase III Trial of the Gynecologic
Cancer Intergroup. J Clin Oncol. 2009;27:1419-1425.
9. Alberts DS, Marth C, Alvarez RD, Johnson G,
Bidzinski M, Kardatzke DR, et al. Randomized
phase 3 trials of interferon gamma-1b plus standard
carboplatin/paclitaxel versus carboplatin/paclitaxel
alone for first-line treatment of advanced ovarian
and primary peritoneal carcinomas: Results from a
prospectively designed analysis of progression-free
survival. Gynecol Oncol. 2008;109:174-181.
10. Aravantinos G, Fountzilas G, Bamias A, Grimani
I, Rizos S, Kalofonos HP, et al. Carboplatin and
paclitaxel versus cisplatin, paclitaxel and doxorubicin
for first-line chemotherapy of advanced ovarian cancer:
A Hellenic Cooperative Oncology Group (HeCOG)
study. Eur J Cancer. 2008;44:2169-2177.
11. Bolis G, Scarfone G, Raspagliesi F, Mangili G,
Danese S, Scollo P, et al. Paclitaxel/carboplatin versus
topotecan/paclitaxel/carboplatin in patients with FIGO
sub-optimally resected stage III-IV epithelial ovarian
cancer a multicenter, randomized study. Eur J Cancer.
2010;46:2905-2912.
12. du Bois A, Herrstedt J, Hardy-Bessard AC, Müller
HH, Harter P, Kristensen G, et al. Phase III trial of
carboplatin plus paclitaxel with or without gemcitabine
in first-line treatment of epithelial ovarian cancer. J
Clin Oncol. 2010;28:4162-4169.
13. Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G,
Zola P, et al. Advanced ovarian cancer: Phase III
randomized study of sequential cisplatin-topotecan
and carboplatin-paclitaxel vs. carboplatin-paclitaxel.
J Natl Cancer Inst. 2010;102:1547-1556.
14. Möbus V, Wandt H, Frickhofen N, Bengala C,
Champion K, Kimmig R, et al. Phase III trial of
high-dose sequential chemotherapy with peripheral
blood stem cell support compared with standard dose
chemotherapy for first-line treatment of advanced
ovarian cancer: Intergroup trial of the AGO-Ovar/
AIO and EBMT. J Clin Oncol. 2007;25:4187-4193.
15. Katsumata N, Yasuda M, Takahashi F, Isonishi S,
Jobo T, Aoki D, et al. Dose-dense paclitaxel once a
week in combination with carboplatin every 3 weeks
for advanced ovarian cancer: A phase 3, open-label,
randomized controlled trial. Lancet. 2009;374:1331-
1338.
Rev Venez Oncol